RARE · Ultragenyx Pharmaceutical Inc.
$26.49
+0.11 (+0.42%)
At close · Aug 14
Market Cap
$2.61B
Shares
98.59M
Ultragenyx Pharmaceutical Inc. Earnings Call Transcripts
Every quarterly earnings call for Ultragenyx Pharmaceutical Inc. (RARE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲11.1%
$90.70M
−$245.11M
'22 Q3
22-11-02
▲23.9%
$103.35M
−$151.83M
'22 Q4
23-01-06
▲25.7%
$100.50M
−$163.97M
'23 Q1
23-05-04
▲21.2%
$108.31M
−$159.83M
'23 Q2
23-08-03
▲8.1%
$98.05M
−$159.65M
'23 Q3
23-10-16
▲23%
$127.14M
−$123.55M
'23 Q4
24-01-08
▲8.3%
$108.83M
−$170.68M
'24 Q1
24-05-02
▲35.7%
$147.03M
−$131.60M
'24 Q2
24-08-01
▲42.3%
$139.49M
−$133.52M
'24 Q3
24-11-05
▲29.5%
$164.65M
−$133.20M
'24 Q4
25-02-13
▲27.7%
$139.00M
−$151.00M
'25 Q1
25-05-06
▲13.6%
$167.00M
−$115.00M
'25 Q2
25-08-05
▲14.7%
$159.93M
−$180.41M
'25 Q3
25-11-04
▲25.8%
$207.07M
−$128.59M
'25 Q4
26-02-12
▼2.2%
$136.00M
−$185.00M
'26 Q1
26-05-05
LATEST
▲28.1%
$214.00M
−$92.00M
'26 Q2
26-08-04
Earnings call
FY26 · Q2
2026-08-04
Ultragenyx Pharmaceutical Inc. Q2 FY2026 Earnings Call
Positive tone
Angelman syndrome Phase III (GTX102) endpoints and design
DTX401 regulatory progress
UX143 (citruzumab) for osteogenesis imperfecta
Revenue
$214.00M
▲ 28.1% YoY Diluted EPS
$-0.90
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Ultragenyx Pharmaceutical Inc. Q1 FY2026 Earnings Call
Confident tone
GTX-102 in Angelman syndrome Phase 3 program
Global commercial expansion
Long-term GTX-102 durability and safety
Revenue
$136.00M
▼ 2.2% YoY Diluted EPS
$-1.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-12
Ultragenyx Pharmaceutical Inc. Q4 FY2025 Earnings Call
Positive tone
UX-111 MPS-3A program and FDA resubmission
Regulatory environment / FDA biomarker scrutiny
2026 financial guidance
Revenue
$207.07M*
▲ 25.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ultragenyx Pharmaceutical Inc. Q3 FY2025 Earnings Call
Confident tone
Crysvita commercial performance and royalty financing
DTX401 in GSDIa clinical results
Other commercial products (Dojolvi, Evkeeza, Mepsevii)
Revenue
$159.93M
▲ 14.7% YoY Diluted EPS
$-1.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ultragenyx Pharmaceutical Inc. Q2 FY2025 Earnings Call
Confident tone
Setrusumab (UX143) Phase III
Commercial Revenue Growth
Crysvita Commercial Performance
Revenue
$167.00M
▲ 13.6% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Ultragenyx Pharmaceutical Inc. Q1 FY2025 Earnings Call
Confident tone
Gene therapy franchise (Sanfilippo and GSD1A) launches
Path to profitability in 2027 and cash management
Citruzumab regulatory path forward
Revenue
$139.00M
▲ 27.7% YoY Diluted EPS
$-1.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Ultragenyx Pharmaceutical Inc. Q4 FY2024 Earnings Call
Confident tone
UX143 / setrusumab osteogenesis imperfecta (OI) Phase 3
GSDIa gene therapy BLA filing
Revenue and commercial growth
Revenue
$164.65M*
▲ 29.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Ultragenyx Pharmaceutical Inc. Q3 FY2024 Earnings Call
Confident tone
Setrusumab / UX-143 for osteogenesis imperfecta (OI)
International expansion (LatAm, EMEA, Japan)
DTX401 for GSDIa gene therapy
Revenue
$139.49M
▲ 42.3% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Ultragenyx Pharmaceutical Inc. Q2 FY2024 Earnings Call
Confident tone
Late-stage clinical pipeline readouts
Setrusumab / Orbit Phase 3 trial
Crysvita commercial momentum
Revenue
$147.03M
▲ 35.7% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Ultragenyx Pharmaceutical Inc. Q1 FY2024 Earnings Call
Confident tone
GTX-102 Angelman Syndrome
Setrusumab Osteogenesis Imperfecta (Orbit/Cosmic)
Regulatory Engagement / FDA Endpoints
Revenue
$108.83M
▲ 8.3% YoY Diluted EPS
$-2.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Ultragenyx Pharmaceutical Inc. Q4 FY2023 Earnings Call
Confident tone
Crysvita commercial performance
GSD1a gene therapy program
GTX-102 Angelman syndrome
Revenue
$127.14M*
▲ 23% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-16
Ultragenyx Pharmaceutical Inc. Q3 FY2023 Earnings Call
Revenue
$98.05M
▲ 8.1% YoY Diluted EPS
$-2.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Ultragenyx Pharmaceutical Inc. Q2 FY2023 Earnings Call
Revenue
$108.31M
▲ 21.2% YoY Diluted EPS
$-2.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Ultragenyx Pharmaceutical Inc. Q1 FY2023 Earnings Call
Revenue
$100.50M
▲ 25.7% YoY Diluted EPS
$-2.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-06
Ultragenyx Pharmaceutical Inc. Q4 FY2022 Earnings Call
Revenue
$103.35M*
▲ 23.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Ultragenyx Pharmaceutical Inc. Q3 FY2022 Earnings Call
Revenue
$90.70M
▲ 11.1% YoY Diluted EPS
$-3.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Ultragenyx Pharmaceutical Inc. Q2 FY2022 Earnings Call
Revenue
$89.34M
▲ 2.7% YoY Diluted EPS
$-2.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ultragenyx Pharmaceutical Inc. Q1 FY2022 Earnings Call
Revenue
$79.94M
▼ 19.6% YoY Diluted EPS
$-2.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Ultragenyx Pharmaceutical Inc. Q4 FY2021 Earnings Call
Revenue
$83.39M*
▼ 8.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Ultragenyx Pharmaceutical Inc. Q3 FY2021 Earnings Call
Revenue
$81.65M
▲ 0.2% YoY Diluted EPS
$-1.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-02
Ultragenyx Pharmaceutical Inc. Q2 FY2021 Earnings Call
Revenue
$86.97M
▲ 40.9% YoY Diluted EPS
$-1.81
▼ 541.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Ultragenyx Pharmaceutical Inc. Q1 FY2021 Earnings Call
Revenue
$99.39M
▲ 173.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Ultragenyx Pharmaceutical Inc. Q4 FY2020 Earnings Call
Revenue
$91.54M
▲ 157.2% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-27
Ultragenyx Pharmaceutical Inc. Q3 FY2020 Earnings Call
Revenue
$81.47M
▲ 215.8% YoY Diluted EPS
$-1.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Ultragenyx Pharmaceutical Inc. Q2 FY2020 Earnings Call
Revenue
$61.71M
▲ 155.5% YoY Diluted EPS
$0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ultragenyx Pharmaceutical Inc. Q1 FY2020 Earnings Call
Revenue
$36.31M
▲ 99.8% YoY Diluted EPS
$-2.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Ultragenyx Pharmaceutical Inc. Q4 FY2019 Earnings Call
Revenue
$35.59M
▲ 118.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 earnings calls
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
327 filings
293 filers
Visit website
Investor relations